TABLE 1.
Strain | Date of isolation (mo/yr) | Origin | Patient’s therapy | Resistance phenotypea | Rifampin MIC (μg/ml) |
---|---|---|---|---|---|
BM4626 | 4/1992 | Bone | Rifampin plus pefloxacin | Tc | 0.008 |
BM4627 | 4/1992 | Pef Rif Tc | 128–256 | ||
BM4364 | 2/1996 | Bone | Vancomycin, followed by rifampin plus pristinamycin | Emc Fos Fus Km Met Pc Pef Tm | 0.008 |
BM4364-R | 3/1996 | Emc Fos Fus Km Met Pc Pef Rif Tm | 256 | ||
BM4365 | 6/1996 | Blood | Rifampin | Pc | 0.008 |
BM4365-R | 10/1996 | Pc Rif | 256 | ||
BM4366 | 1/1997 | Skin | Rifampin | Pc Emc | 0.008 |
BM4366-R | 1/1997 | Pc Emc Rif | 128–256 | ||
BM4367 | 3/1997 | Urine | Rifampin plus vancomycin | Emc Fos Km Met Pc Pef Tm | 0.016 |
BM4367-R | 4/1997 | Urine and pulmonary tree | Emc Fos Km Met Pc Pef Rif Tm | 4 | |
BM4368 | 3/1997 | Urine | Rifampin plus vancomycin | Pc Tc | 0.016 |
BM4368-R1 | 3/1997 | Pulmonary tree | Rifampin plus vancomycin | Pc Rif Tc | 128 |
BM4368-R2 | 4/1997 | Pulmonary tree | Pc Rif Tc | 4 |
Emc, constitutive resistance to macrolide, lincosamide, and streptogramin β-type antibiotics; Fos, resistance to fosfomycin; Fus, resistance to fusidic acid; Km, resistance to kanamycin; Met, resistance to methicillin; Pc, resistance to penicillin G; Pef, resistance to pefloxacin; Rif, resistance to rifampin; Tm, resistance to tobramycin.